Further, we discovered that both mAbs could revitalize immune checkpoint therapy even after tumor cells had developed resistance to it.34 As such, anti-PCSK9 mAbs, used either independently or in combination with ICI or alternative immunotherapies, possess considerable potential for antitumor therapy. Here, PCSK9 is linked to neoplasm.